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The European Society for Vascular Medicine (ESVM) 
This Society aims to develop the specialty of vascular medicine in Europe in order to improve the 
vascular health of the population and to improve the quality of life and health status of vascular 
patients.  ESVM engages in promotion of scientific exchanges, education, cooperative research and 
quality of care in the field of arterial, venous, lymphatic and microvascular diseases. As part of its 
endeavour to improve the medical care of vascular patients a series of Guidelines, filling gaps in the 
literature, are being written. Each of the ESVM member Country’s Society endorses the Guideline 
after review and comment. The European Society for Vascular Medicine is an excellent opportunity 
to bring together experts from 16 different countries who regularly manage patients with Raynaud’s 
phenomenon, in order to propose a consensual approach to the practical problems encountered by 
patients with Raynaud's phenomenon and their attending physicians. 
The Need for Guidelines for the Diagnosis and Management of Raynaud’s Phenomenon 
Raynaud phenomenon (RP) is highly prevalent in the general population (prevalence 3-21% 
depending on the climate)1. The literature regarding its clinical diagnosis, associated conditions, 
investigations and treatment is substantial, and yet no international consensus has been published 
regarding the medical management of patients presenting with this condition. For example the use 
of syndrome, phenomenon and disease appears arbitrary in terms of the nomenclature, systematic 
diagnostic investigations proposed in the literature vary from nil to extensive workups, and the 
therapeutic strategies also vary tremendously2.  
Most knowledge on this topic derives from epidemiological surveys and observational studies; few 
randomized studies are available, almost all relating to drug treatment and thus these guidelines 
were developed as an expert consensus document to aid in the diagnosis and management of 
Raynaud’s phenomenon. This consensus document starts with a clarification about the definition 
and terminology of Raynaud’s phenomenon, and covers the differential and etiological diagnoses as 
well as the symptomatic treatment. 
Aims and Goals of Raynaud’s Guideline 
The aim of this Guideline is not to replace expert opinion on individual cases but to allow the 
General Practitioner (GP) in Primary Care insight into the different types of Raynaud’s, the 
mechanisms for diagnosis/differential diagnosis, and early management. As patients with Primary 
Raynaud’s may be managed in Primary Care/Family Practice, a Guideline which clarifies these points 
will allow appropriate referral to Secondary Care for the small, but significant, proportion of 
Raynaud’s patients who require this (see later for recommendations for referral). This Guideline 
aims to help such staff make appropriate onward referral where appropriate. It aims to inform GPs 
about associated conditions in Secondary Raynaud’s, and alert the GP to early symptoms /signs 
/markers of Secondary Raynaud’s to ensure appropriate referral to Secondary Care. 
We hope also that the Guideline will be useful for non-specialist Secondary Care staff who may be 
referred such patients in general clinics. It should be noted that this Guideline deals only with the 
management of Raynaud’s, and not of any disorder to which RP is secondary eg Connective Tissue 
Disorders (CTDs). 
We hope to inform about investigations in Primary Care for the Raynaud’s itself, and importantly for 
exclusion/confirmation of secondary Raynaud’s. The issue of management in Secondary Care will be 
covered in the Raynaud’s Phenomenon Guideline II. 
Methods of Assessment and Strength of Recommendations 
The following provides a Key to levels of evidence and grades of recommendations that were used in 
this Guideline (Modified from the two other European Vascular Societies for consistency ie European 
Society of Cardiology, (ESC)3 and European Society of Vascular Surgery (ESVS). 
LEVELS OF EVIDENCE 
Level A: Data derived from many randomised controlled trials (RCTs) or from meta analyses 
Level B: Data derived from one RCT or from large non-randomised clinical trials 
Level C: Consensus from experts, or data from small studies, registries or retrospective studies 
GRADES OF RECOMMENDATION 
Note: The grade of recommendation relates to the strength of the evidence. It is not a measure of 
the clinical importance of the recommendation.  
Grade I: Evidence that a treatment or procedure is beneficial, and effective 
Grade II: Conflicting evidence and /or differences in opinion in experts regarding the benefit/efficacy 
of the treatment/procedure 
Grade IIa: The weight of evidence or opinion is in favour of benefit/efficacy 
Grade IIb: Benefit/efficacy is less well established 
Grade III: Evidence or agreement that the treatment is not of benefit nor is it efficacious, and in 
some cases may be harmful. 
Definition and Nomenclature of Raynaud’s 
 In 1862 Maurice Raynaud described a phenomenon of transient and reversible attacks of color 
changes triggered by cold exposure, associated with various conditions leading to different 
outcomes, which he ascribed to an ischemic mechanism4. However even from the beginning the 
nomenclature used was not standard. The title of his thesis "De l'asphyxie locale et de la gangrène 
symétrique des extrémités", and the focus on the trophic changes in its first English shortened 
translation led to many workers naming conditions such as digital gangrene, digital ischemia and 
digital ulcerations after Maurice Raynaud. Over the last twenty years, however, clarification has 
been progressively observed in the literature, restricting the use of the ‘Raynaud’ name to its initial 
clinical description of cold induced ischemic attacks of the extremities manifested by transient 
reversible digital colour changes. Thus Raynaud’s Phenomenon (RP) is the over-arching term for the 
condition of digital vasospasm producing blanching. 
Further clarification is needed regarding the terms "Raynaud disease" and "Raynaud syndrome". 
These terms were coined in order to differentiate the two main etiological subsets of Raynaud 
phenomenon: Raynaud’s Disease where there is no associated or underlying disorder and Syndrome 
where there is.  Unfortunately, both these denominations have drawbacks: 
- Raynaud Disease is used as a synonym for primary RP. However, it is a benign condition,
affecting 3 to 21% of the general population1 and not associated with any tissue loss or
progression under normal circumstances; as clinicians, we would like to reassure those
patients and avoid an unnecessary medicalization. The use of the word “disease” is thus not
helpful.
- Where the Raynaud’s is associated with other disorders it is indeed a syndrome, since it
associates several signs and symptoms, and may be related to many etiologies. The usual
classification of RP as a vascular acrosyndrome is consistent with this view. Raynaud’s
syndrome (RS) may occur with many other conditions and takes its prognosis from these
rather than from the RS itself.
However as there is no additional value in the use of these terms, we propose to avoid any other 
denomination but primary or secondary Raynaud’s phenomenon. Such consistency of terminology is 
crucial because of the need for standardisation to allow epidemiology and therapeutic trials of 
defined populations. 
Recommendation 1:  
Raynaud’s Phenomenon is the correct term for this disorder. It may take the form of Primary 
Raynaud’s Phenomenon or Secondary Raynaud’s Phenomenon.  
Epidemiology and Symptoms of RP 
There is an initial blanching of the skin resulting from vasospasm, usually followed by cyanosis due to 
deoxygenation of the static venous blood and lastly by rubor as a consequence of reactive 
hyperaemia after return of flow, producing the classical ‘triphasic colour change’. However this  
classical triphasic colour change is not always present (occurring in about one-third of primary RP 
patients, and two thirds of secondary RP associated with systemic sclerosis5) but blanching must be a 
feature in order for the diagnosis of RP to be made. As cyanosis and rubor are not always present, it 
should be remembered that blanching alone can also allow the diagnosis of RP to be made.  
The color changes start at the tip of the finger and spread to one, two or three phalanges, or more 
fingers.  
- the demarcation of the color changes is usually clear-cut, and involves both volar and dorsal
aspects ie it is circumferential
- there is almost always associated transient numbness of the affected finger tips, often with
paraesthesia on rewarming.
- Vasospasm may be systemic affecting other extremities eg nose, ears, tongue, and may be
associated with other vasospastic disorders such a migraine, irritable bowel, and
microvascular chest pain6.
PRIMARY RAYNAUD’S PHENOMENON (PRP) 
Classically PRP presents as symmetrical vasospasm, usually affecting both hands brought on by a 
number of stimuli including cold and emotion, but also carrying objects. The thumbs are often 
spared. It tends to begin at a younger age than secondary RP. Trophic changes are not seen in 
Primary RP. If trophic changes are seen the search for an underlying condition must be thorough. 
PRP is nine times more common in women than men and has an overall prevalence of 10%, although 
it may affect as many as 20 – 30% of women in the younger age groups2. The proportion affected 
within a population depends on local climate1. In addition to digital vessel involvement, patients 
with RP may experience symptoms in the tongue, ear lobes, tip of the nose and the nipples, and 
there is a high incidence of migraine in these patients. By far the largest group of patients presenting 
to their Primary Care physician are those with primary RP, which typically occurs in young women in 
their teens and 20s, has a familial predisposition and accounts for the vast majority of all cases of RP. 
SECONDARY RAYNAUD’S PHENOMENON (SRP) 
In contrast, more than 50% of the patients with RP referred to secondary or tertiary care will have an 
associated underlying systemic disease. Trophic changes are seen in secondary RP, particularly in RP 
associated with CTDs. There may also be symptoms of the associated disorder at the time of 
presentation.  
The predictors for the RP attack rate, severity and pain are low average daily temperature, stress, 
anxiety, older age and female gender. Recent studies have shown that the RP may predate systemic 
illness by up to two decades. The occurrence of certain clinical features may suggest a greater 
likelihood of disease progression to CTD (Table 1). For instance, sclerodactyly (puffy fingers with skin 
tightening) and pitting scars over the finger pulp are associated with later development of other 
features of CTD and may allow fulfilment of the 2013 ACR-EULAR classification criteria for systemic 
sclerosis7. 
Recommendation 2 
The terms Primary Raynaud’s Phenomenon and Secondary Raynaud’s Phenomenon should be 
used and the terms ‘syndrome’ and ‘disease’ discarded. 
Grade IIa - Level C  
OTHER VASCULAR ACROSYNDROMES / DIFFERENTIAL DIAGNOSES 
Vascular acrosyndromes define any condition either primary or secondary, either vasospastic or 
obstructive, that induces disturbances in the cutaneous microcirculatory network of the extremities. 
They include RP, acrocyanosis, livedo and erythromelalgia. Differential diagnosis has also to be made 
with related conditions including chilblains, cold injuries and paroxysmal digital hematoma. 
- Primary acrocyanosis is a benign condition often found in young women with low BMI, often
with anorexia, which associates painless distal symmetrical cyanosis of the upper limbs or all four
extremities, with coldness and sometimes palmar or palmo-plantar hyperhidrosis due to
sympathetic overdrive. The degree of cyanosis worsens in winter and during cold exposure and
decreases in summer, but there is no attack, no demarcation, and no numbness8. However, this
benign condition can be associated with a genuine primary RP, most often a white only RP, due to
the common thermoregulation related risk factors they share. The lack of fat insulation augments
the normal vasoconstrictive response to cold in the digital vessels.
- Livedo is a relatively common physical finding consisting of a red to blue mottled netlike
discoloration of the skin of the lower (more frequent) and upper limbs, potentially of the whole
body. The literature is often confusing because different synonyms are reported such as livedo
reticularis (complete rings), livedo racemosa (incomplete rings), purpura retiform (incomplete rings
and subcutaneous local necrosis), cutis marmorata, reticular cyanosis, livedo annularis. Livedo is
secondary to organic or functional disorders of the efferent dermo-hypodermal arterioles that will
induce deoxygenation in the superficial venous plexus. Possible causes include: vasospasm caused by
cold (primary/idiopathic livedo), arterial embolism, increased blood viscosity, Sneddon’s syndrome, 
some drugs including phenylbutazone, and vasculitis (secondary livedo)9.   The idiopathic form 
affects especially young women and is benign. Only the primary/idiopathic form fades when lifting 
or warming limbs. A complete work-up is needed when a secondary form is suspected. 
- Chilblains (Pernio) often occur in patients with acrocyanosis, as oedematous papules of
deeper hue in the extremities, such the finger or toe pads, but also the nailfolds and the skin of
dorsum of the feet and hand at the level of the small digital joints. They are pruriginous and can be
painful. Their location on the finger pads could be confused with a permanent area of digital
ischemia associated with a secondary RP rather than with a benign RP, but the pain is much milder
and the itch pronounced. They are more frequent in association with RP. They consist of
inflammatory cutaneous lesions in patients exposed to non-freezing weather (and damp conditions)
during late winter or early spring. The lesions typically present as painful erythematous or purple
lesions with associated swelling or itching (sometimes with cutaneous necrosis, ulceration or
blistering) of the fingers or toes (or both): they are frequently misdiagnosed as vasculitis or embolic
events. Chilblains are a self-limiting process that usually resolves within 1 to 3 weeks10.
- Erythromelalgia ( = Erythermalgia) (EM) is a symptom complex characterised by: 1) burning
pain in the extremity, 2) pain worsened by warming, 3) pain relieved by cooling, 4) erythema of
affected skin, and 5) increased temperature of affected skin11.  The symptoms and findings are most
often intermittent and may not present during physical examination.  Two forms exist: Primary and
Secondary. Primary is a true primary vasodilatory disorder, secondary EM may be related to two
broad causes: a) vasospastic in origin, where the blanching is absent and the burning erythema is
due to a reactive hyperemia. This latter occurs most commonly in association with risk factors for
atherosclerosis; and b) in myeloproliferative syndromes and these symptoms are more often
improved by aspirin and sometimes referred to as erythromelalgia.
- Paroxysmal Digital Hematoma (Synonyms: Achenbach syndrome, orange ecchymotique,
digital venous apoplexy, spontaneous digital haematoma, haemorrhagic phlebodystonia).  It
presents with a sudden acute pain in a finger, rarely in the palm or a toe. The onset is spontaneous
or after a minor mechanical stimulus. A painful tension persists for hours and an ecchymosis appears
in the affected area. The concomitant oedema may impair movements of the finger. The 2nd, 3rd and
4th fingers are commonly affected. Symptoms and signs fade spontaneously over a few days. Very
rarely a digital venous thrombosis may complicate the clinical picture. Pathogenesis can be ascribed
to spasm and rupture of a venule. The syndrome mostly affects women in the 4th to 6th decades.
Frequently, another vascular primary acrosyndrome coexists12 (acrocyanosis, chilblains, primary RP).
- Non-freezing cold injuries (NFCI) occur when tissue fluids do not freeze (usually at about –
0.5° C), but local temperatures remain low for several hours or days. NFCI are probably often
unreported and under-diagnosed. There is often a history of having been cold and wet for a
sustained period and having been unable to dry out fully. On rewarming, the affected limb shows a
localised sensory neuropathy. There are generally few other objective clinical signs. In severe cases
there is cold sensitisation so that individuals are unable to work outside developing oedema,
hyperhidrosis and/or chronic pain resembling algoneurodystrophy13.
- Frostbite is true tissue freezing caused by heat loss sufficient to cause ice crystal formation
in superficial or deep tissues: there is the evidence of the role of thromboxanes and prostaglandins
in the tissue damage13. The spectrum of injury is varied, from minimal tissue loss with mild long term
sequelae, to major necrosis of the distal limbs with subsequent major amputations and phantom
limb pain.
Associated Conditions in Secondary Raynaud’s 
The early diagnosis is important as RP is often the presenting feature of CTD and therefore provides 
an opportunity for early diagnosis. Early management might prevent morbidity and might save lives. 
Introduction of organ screening early in associated diseases has been shown to be associated with 
reduced disease progression and better outcomes14. Most cases of severe RP are associated with 
CTDs. RP occurs in 90% of patients with systemic sclerosis (SSc) and is often perceived to be their 
most pressing clinical problem.  It also occurs in the other CTDs: 85% of patients with mixed CTD, 
between 10% and 45% of patients with systemic lupus erythematosus, 33% of patients with 
Sjögren's syndrome and 20% of those with dermatomyositis/ polymyositis experience RP. Patients 
with rheumatoid arthritis have a similar overall prevalence of RP as compared with the general 
population (10%); however, symptomatology tends to be more severe. 
Patients presenting for the first time in their third to fifth decade are at high risk of developing CTDs. 
In RP occurring in very young children, an underlying CTD should be considered, especially if the 
symptoms include blanching and are severe. In patients with the limited cutaneous subtype of  SSc, 
RP commonly precedes the diagnosis of CTD by several years, , conversely rapid appearance of skin 
changes around the same time as the onset of RP  is suggestive of  diffuse cutaneous SSc. Systemic 
enquiry should concentrate on the presence of migraine (or a family history of migraine), , and the 
presence of a family history of Raynaud’s (usually markers of primary RP) and musculoskeletal 
symptoms associated with CTD.. 
A full physical examination should be directed to look for any obstructive vascular disease and for 
signs of associated autoimmune conditions. Simple blood pressure measurement in both arms will 
help to detect significant occlusive vascular disease above the brachial artery. Livedo reticularis 
could point to cold agglutinin disease or underlying CTD. Patients with abnormal nail fold microscopy 
are more likely to progress to a CTD (see later). 
Various drugs can precipitate or exacerbate RP. Of these B- blockers are the most frequently 
prescribed culprits. The newer generation of vasodilating B-blockers, however, seem to be safer in 
RP sufferers. In the older age group, obstructive vascular disease is the most common cause of RP 
and it has been reported that 60% of RP occurring in individuals older than 60 years is 
atherosclerotic in origin. In workers exposed to vibration hand-hammer syndrome must be 
considered. Hand-arm vibration syndrome (HAVS), previously known as vibration white finger 
syndrome is the most common form of occupational RP with a prevalence of 50% in all workers 
using vibrating tools for any significant period of time.  
Other conditions associated with RP are listed in Table 1. Table 2 list conditions which might worsen 
already an established tendency for RP, and Table 3 is where microvascular obstruction mimics RP. 
Again it is important to note that research is needed to clarify progressively what is associated with 
SRP and to be sure that some PRP are true PRP. For example, bariatric surgery, in the opinion of 
some experts, could be associated with the development of RP because of an important loss of 
weight and thermoregulation dysfunction. However no study has been done to assess this 
association. Moreover it is possible that some RP considered as PRP could be SRP if future studies 
confirm the possible role of cryofibrinogenaemia15. 
Table 1: The conditions which may be associated with secondary RP. 
Connective Tissue Disorders 
• Systemic Sclerosis
• Systemic Lupus Erythematosus
• Mixed CTD
• Sjögren’s Syndrome
• Dermatomyositis/Polymyositis
• Primary Biliary Cirrhosis (often with underlying SSc)
Occupational 
• Hand Arm Vibration Syndrome and Hypothenar Hammer
Syndrome
• Vinyl Chloride Monomer exposure
• Silica and solvents (causing systemic sclerosis)
Drugs 
• Anti-migraine drugs eg ergot derivatives
• Non-selective β Blockers, including eye drops
• Some Cytotoxic drugs
• Cyclosporin (though may be obstructive especially in
transplant patients)
• Bromocriptine
• Interferon α  and β
• Cocaine or amphetamine abuse, cannabis
• Estrogen replacement therapy without progesterone
• Ephedrine eg in Ear Nose and Throat preparations
Endocrine 
• Hypothyroidism
• Pheochromocytoma
Paraneoplastic (eg carcinoid) 
Miscellaneous 
• Buerger’s disease (Thromboangiitis obliterans)
• Low BMI
• Following Bariatric Surgery
• Complex Regional Pain Syndrome
• Frostbite sequelae
• Digital injury sequelae
However it should be noted that there are a large number of historically ‘associated conditions’ but 
these often have different etiologies: 
- A large subgroup of these listed conditions (such as some drug induced necrosis, cancer and
hematological disorders associated with thrombosis or vasculitis of any cause, or even frostbite) are
digital necrosis often due to small vessel occlusion, not RP, their presence in the list being remnants
of the nosological confusion explained above. It should be noted that cold injury, however, can
result in RP in the damaged area afterwards and this included frostbite. Rarely, a true RP can be
associated with these conditions, but only as sequelae of previous ischemic trophic changes, and in
the exact location of these trophic changes. They do not need to be considered in patients with
isolated RP and no history of such changes.
- Any condition increasing vasoconstriction can worsen a pre-existing RP (vasoconstrictive
drugs, hypothyroidism and pheochromocytoma). In these cases, as in other instances, there is an
underlying true RP etiology, which is worsened by the underlying disease, and sometimes several
associated factors can be found in the same patient (e.g. a patient with hypothyroidism and carpal
tunnel syndrome, and an underlying limited systemic sclerosis). Indeed, a multifactorial RP is not an
uncommon, and the detection of one factor should not close the etiological evaluation.
- RP was once thought to be a rare condition. However, its real prevalence is quite substantial
in the general population, however some conditions often associated with RP are not, in fact, more
prevalent in RP subjects than in the general population. This has been shown at least for carpal
tunnel syndrome and for thoracic outlet syndrome. However, the pattern of the attacks is often
influenced by the associated condition (asymmetrical RP predominant in the medial nerve territory
for carpal tunnel syndrome, in C8-D1 territory for the thoracic outlet syndrome). As they do not
influence the prevalence, from an epidemiological point of view, these factors cannot be considered
true etiologies, but only worsening factors, and again, their detection in RP patients should not end
the etiological evaluation.
Table 2: Condition which may worsen existing Raynaud’s 
Anatomical 
• Thoracic outlet syndrome
• Carpal Tunnel Syndrome
Drugs 
• As for Table 1
Atherosclerosis 
Cigarette Smoking 
Table 3: Conditions where microvascular occlusion may mimic Raynaud’s and should be excluded 
Occlusive vascular disease 
• Embolism (eg from thoracic outlet syndrome)
Haematological 
• Malignancies
• Cryo diseases (cryoglobulinaemia, cryofibrinogenaemia and cold
agglutinin disease)
• Hyperviscosity Syndromes
Infection 
• Hepatitis associated vasculitis
Recommendation 3 
Conditions associated with RP should be divided into true associated disorders with etiological 
links; those which worsen RP or precipitate its appearance; and those which do not cause 
vasospasm but digital necrosis. 
Grade IIb - Level C 
Diagnosis in Primary Care 
HISTORY TAKING IN THE PATIENT WITH RAYNAUD’S 
• A history of Raynaud’s symptoms will diagnose RP if there is a clear history of well
demarcated blanching (+/- cyanosis/rubor). Ask age of patient at onset of RP, about
frequency of attacks, whether associated with numbness, paraesthesia on
rewarming or pain. Asking patients to photograph their fingers during an attack can
often help secure the diagnosis. As PRP is an augmentation of the vascular response
to temperature, such patients may also have ‘excessive’ vasodilatory responses to
warmth, alcohol and spicy food affecting not only the fingers but face and chest
wall.
• Taking a clear history will help to diagnose CTD or other associated cause. Important
symptoms to elucidate are photosensitivity, mouth ulcers, tightening of the skin,
dryness of eyes or mouth. Drug history should be taken, as should occupational
history to look for hand arm vibration syndrome. In PRP a family history is often
present.
• A history of migraine, irritable bowel, anorexia i.e. systemic vasospasm symptoms
elsewhere is more likely to be PRP.
EXAMINATION OF THE PATIENT WITH RAYNAUD’S 
• On examination check for colour change, but the time the patient has been in the
warm waiting room may have attenuated an attack (thus the usefulness of a
photograph), and rubor alone may be witnessed as the hands rewarm. Check the
peripheral pulses to exclude obstructive vascular disease.
• Look for signs of poor tissue nutrition such as trophic changes in the nails, digital
pitting, hacks or ulcers. Chilblains can co-exist in PRP. Digital ulcers are not seen in
PRP and are a strong pointer to SRP.
• Look for signs of an associated disorder. Key signs include widespread telangiectasia,
sclerodactyly, tightening of the skin elsewhere especially round the mouth, malar
rash, synovitis, and patchy alopecia.
• Blood pressure should be checked in both arms where there is asymmetrical RP.
• Allen's test is mandatory for the detection of distal arterial disease of the upper
limbs. The hand is elevated and the patient is asked to clench their fist for about 30
seconds. Pressure is applied over the ulnar and the radial arteries so as to occlude
both of them. The occlusion is released one artery at a time. If color returns quickly
as described above, Allen's test is considered to demonstrate normal circulation. If
the pallor persists for some time after the patient opens their fingers, this suggests a
degree of occlusion of the uncompressed artery
Recommendation 4  
A thorough history and examination should be taken from all patients presenting in Primary Care 
to ensure correct diagnosis of any underlying condition, as early diagnosis and organ screening in 
CTD improves outcome. 
Grade IIa - Level C   
RECOMMENDED PRIMARY CARE TESTS IN THE PATIENT WITH RAYNAUD’S 
• Blood tests: Where there is any suspicion at all of a secondary RP some basic blood
tests can be helpful. Antinuclear antibody (ANA) titers, should be measured16. If the
ANA screen is positive an ENA may be helpful. The ENA screen may turn up anti-
topisomerase antibodies associated with diffuse systemic sclerosis, anti-centromere
antibody withlimited systemic sclerosis, anti Ro or La with Sjögrens, and a positive
anti DNA titre is suggestive of SLE. A full blood count will exclude many disorders,
thyroid function should be checked. A CRP will detect inflammation (note: a normal
CRP does not exclude CTD). Plasma viscosity or ESR will also measure inflammation.
Unless symptoms or signs direct otherwise this is usually a sufficient Primary Care
screen.
• Urine: A Dipslide urinalysis can be useful in picking up renal involvement in
conditions such as SLE.
• Capillary microscopy: Abnormalities of the nail fold vessels as detected by
capillaroscopy is one of the most sensitive ways to detect early CTD17. However this
is not usually performed in Primary Care, although a number of clinicians do use
dermatoscopy for skin lesions such as differentiating mole from melanoma, and this
can be used to visualise the nail fold vessels. However low power (x10) can miss
early changes. An early referral to a Secondary Care physician practising
capillaroscopy is recommended. Capillaroscopy plus more selective
immunopathology tests can help the Secondary Care physician exclude or confirm
CTD rapidly in most cases18.
• Other tests: Secondary Care may carry out additional tests, predominantly blood
tests for underlying disease, but also vascular tests such as plethysmography, cold
challenge etc. However these are neither possible, nor desirable for all patients in
Primary Care and are not covered in this Guideline.
Recommendation 5 
All patients presenting with RP should undergo blood tests including full blood count, ESR or CRP, 
and ANA testing, and capillaroscopy when available.  
Grade IIa - Level C 
Recommendation 6 
Capillaroscopy should only be carried out using equipment of good optical quality and by an 
experienced operator, usually in Secondary or Tertiary Care. 
Grade IIa - Level C 
Recommendation 7 
Capillary microscopy is a useful diagnostic tool. Abnormal capillary patterns are strong predictors 
of CTD, and should be employed by Secondary Care. 
Grade IIa - Level B 
Referral to Secondary Care 
• The majority of patients seen in Primary Care will have PRP, however missing early
CTD or other associated cause can have serious consequences, as organ involvement
in CTD can be asymptomatic until extensively progressed.
• Any symptom, sign or blood test as above that raises suspicion of a SRP should alert
the physician to refer to Secondary Care
• RP associated with vibration requires referral to vascular clinician with expertise in
this area or an Occupational Physician.
• Referral is recommended if there is any suspicion of a SRP, if any isolated signs of
SRP are detected (such as digital ulcer), the patient has an abnormal ESR/CRP/blood
count, and an abnormal ANA and ENA screen. However RP can be the precursor of
CTD by many years and any worsening symptoms should trigger a referral
• Recommendation of referral to Secondary or Tertiary Care should also be
considered if the RP is severely symptomatic, and unresponsive to standard
treatments.
• Consideration should be given to secondary referral of children under the age of 12
as PRP may be  less common in the younger age groups. A high index of suspicion
should be applied.
Recommendation 8 
Children under the age of 12 should be referred to Secondary Care as PRP is less common in these 
age groups 
Grade IIa - Level C  
Recommendation 9  
Patients with RP should be referred to Secondary Care when 
• There is evidence of an associated disorder or of occlusive vascular disease
• Symptoms are severe or progressing despite first line lifestyle and drug treatment
Grade IIa - Level C  
Management of Raynaud’s 
Not all patients experiencing digital vasospasm require drug treatment, but potential prescribers 
should be aware that the severity of the pain produced by vasospastic attacks and the degree of 
interruption that patients may experience in their normal daily routine may be profound. The aim of 
therapy is to provide symptom relief and improve quality of life. Management of RP depends on 
severity: for example, management of a patient with mild primary  RP will be very different from 
that of a patient with severe RP secondary to systemic sclerosis, who has progressed to digital 
ulceration.   
GENERAL MEASURES INCLUDING LIFESTYLE CHANGES 
 Education and avoidance of triggers are key.It is important to advise patients about protecting 
themselves from the cold. Lifestyle measures such as wearing gloves when handling frozen food 
should be adopted. Simple suggestions such as keeping the trunk warm, and providing occupational 
therapy aids such as key holders to use when the fingers are numb can all help. Education is 
important, and an occupational therapist can provide useful advice, as can patient self-help groups. 
It is essential that patients with RP stop smoking and, where applicable, avoid vibration exposure. 
Initial treatment in mild disease is conservative, and drug treatment reserved for those patients who 
do not respond to these conservative measures.  Electrically heated gloves and socks and chemical 
hand warmers are helpful in some patients. 
In the case of HAVS, early diagnosis and early discontinuation of vibration exposure may resolve the 
problem. Withdrawal of vasoconstrictor drugs should be considered when possible.  Although the 
contraceptive pill has been linked anecdotally to the development of Raynaud’s phenomenon, this 
has never been conclusively proven. In the management of digital ulceration in patients with severe 
RP, it is essential to treat any infection aggressively and quickly.  
Recommendation 10 
Lifestyle change is an effective means of controlling RP attacks and should include avoiding 
triggers such as cold, dressing warmly, ceasing smoking, and an Occupational Therapy assessment 
for aids if difficulties are reported. 
Grade IIa - Level C  
DRUG TREATMENT 
Patients whose symptoms interfere with either their social or working lives, and who have not 
responded adequately  to 'general' measures should be considered for drug therapy.  
Calcium channel blockers: Calcium channel blockers, for example  nifedipine,  are the first line drug 
treatment for RP. A meta-analysis of RCTs showed that nifedipine reduced both the number and 
severity of RP attacks19.  A recent Cochrane review of calcium channel blockers in primary PRP20 , 
which included 296 patients in seven clinical trials, found that calcium channel blockers were only 
minimally effective, with 1.72 (95% confidence intervals 0.60 to 2.84) fewer RP attacks per week on 
calcium channel blockers compared to placebo. However, this was in the context of small same sizes, 
and 'variable data quality'. Many clinicians prefer long acting/delayed release preparations, as the 
short-acting preparations are more likely to produce  vasodilatory adverse effects and their action 
lasts only a few hours. The recommended dosage range for nifedipine is from 10 to 20 mg two or 
three times a day. Starting at a low dose minimises side-effects however the 10mg preparation is not 
available in all European Countries. Better tolerance of side effects can be obtained by introducing 
the drug slowly eg 10mg at night for two weeks, then in the morning for two weeks then bd etc. 
Adverse effects may disappear after a few weeks on treatment and patients should be encouraged 
to remain on therapy unless the vasodilatory side effects are intolerable. If adverse effects force 
discontinuation of nifedipine then other calcium channel blockers can be used21. These include 
amlodipine, lercanidipine or diltiazem. It should be noted that nifedipine has not been passed for 
use in children <18 years of age or in pregnancy. 
Recommendation 11 
Calcium channel blockers are the recommended first line drug treatment for RP, if life-style 
modification alone has failed. 
Grade I - Level A  
Recommendation 12 
Nifedipine in slow release form should be used to minimise debilitating vasodilatory side effects 
and short duration of action. Care should be taken to increase dosage by increments to avoid side 
effects. If side effects are not severe patients should be encouraged to tolerate them for 2 – 3 
weeks as they may subside. 
Grade IIa - Level C  
Other vasodilators: Treatment with other vasodilators remains controversial, as most studies have 
been uncontrolled or contain very few patients. A Cochrane review of vasodilators other than calcium 
channel blockers for primary RP22 highlighted the lack of evidence base to support the use of any of 
other vasodilators, and calcium channel blockade is the main stay of treatment in Primary Care. 
Nonetheless, if a patient does not respond to a calcium channel blocker, because of either inefficacy 
or intolerance,  then it seems reasonable to try another vasodilator23 Some clinicians favour the 
angiotensin receptor antagonist, losartan, which showed benefit in a head to head open label trial 
against nifedipine but no further studies have yet been published. Fluoxetine24, an SSRl, was compared 
to nifedipine in an open-label cross-over study including patients with both primary and secondary RP 
and conferred benefit in terms of frequency and severity of attacks. Fluoxetine may be beneficial in 
patients intolerant to other therapies which are more likely to cause vasodilatory side effects.   
Newer vasodilatory drugs are under study but evidence is not yet available to support their use in 
primary RP. These include phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil)25 and 
phosphodiesterase-3 inhibitors such as cilostazol. However, phosphodiesterase-5 inhibitors  are 
being increasingly used in systemic sclerosis-related RP, with a number of recent trials26,27,28,29 and a 
meta-analysis25 suggesting benefit, although the trials were all of short duration and  large, long 
duration controlled trials are required. Topical nitrates have recently been revisited.  A multicentre, 
placebo-controlled trial (which included patients with both primary RP and secondary RP, most of 
whom had systemic sclerosis) demonstrated benefit from a novel formulation of glyceryl trinitrate 
(GTN),  MQX-503 in terms of improvement in Raynaud's Condition Score. MQX-503 gel was applied 
to the fingers immediately before or within 5 minutes of onset of a Raynaud's attack over a 4 week 
period, and was applied for its local (as opposed to its systemic) effect30. 
Prostaglandins: Prostaglandins (PGs) have potent vasodilatory and antiplatelet properties. 
Intravenous treatment with PGI2, its analogues such as Iloprost31, and PGE132 have been shown to 
be beneficial however intravenous administration is a drawback. Oral PGs have been shown to be 
ineffective in their current form34. A recent multicentre study of oral treprostinil in patients with 
systemic sclerosis-related digital ulcers35 showed a small but statistically insignificant reduction in 
net ulcer burden compared to placebo after 20 weeks treatment. A meta-analysis36 and RCTs have 
shown benefit with IV iloprost, and treatment with PGs is recommended if nifedipine fails. However 
these treatments must be administered in Secondary Care due to the need for IV infusion, and 
monitoring of vasodilatory side effects such as hypotension, and so tend to be reserved for patients 
with severe RP secondary to connective tissue diseases, often with digital ulceration. Compared to 
nifedipine PGs are as effective at symptom resolution, and better at ulcer healing.  
Other medical therapies37: Endothelin-1 receptor antagonists also have been investigated. Bosentan 
has been evaluated as a treatment of digital ulceration secondary to SSc and conferred benefit in 
two multicentre RCTs38,39 in terms of prevention of new ulcers, although it had no effect on healing 
of existing ulcers.  However its use for pure (uncomplicated) RP has as yet no evidence base and 
cannot be recommended.  
Surgery: This has no role to play in primary RP but may be indicated in patients with secondary RP 
who have progressed to digital ulceration and/or gangrene. Surgical debridement/operations to 
remove some of the terminal phalanx and occasionally amputation40 are necessary in Secondary Care 
for digital necrosis, but with iloprost treatment this is rare. Upper limb sympathectomy is no longer 
recommended due to observational studies failing to show any benefit. Localized digital 
sympathectomy has attracted increasing interest in recent years, especially in patients with digital 
ulceration (often in the context of systemic sclerosis) and a number of case series and observational 
studies have now been reported41.  Digital sympathectomy is a highly specialised procedure, 
performed only in specialist centres. Although a systematic review indicated that there is no good 
evidence base for surgical procedures (including sympathectomy) for RP35, this is unsurprising given 
the small numbers of patients coming to surgery and the difficulties inherent in running clinical trials 
of surgical procedures.  
Recommendation 13 
No good evidence exists in support of surgical management of RP, but this may be indicated in 
certain situations, for example systemic sclerosis-related digital ulceration. Grade IIb - Level C 
Areas where evidence lacking/areas for further study 
As can be seen in this Guideline there are few areas of robust evidence in this field42. Further areas 
for study include large RCTs of the novel therapies described above, validation of nifedipine in a slow 
release preparation as a useful treatment (allowing Primary Care physicians to use this as first line 
versus the currently licensed short acting form). All surgical procedures should be subjected to RCTs 
(if feasible) or well-designed observational studies. 
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